Change page: Don't use aspirin for primary prevention of cardiovascular disease

BMJ (Online)

Volumn 340, Issue 7752, 2010, Pages 920-

  Barnett, Helen ^a   Burrill, Peter ^b   Iheanacho, Ike ^a  

^a BMJ   (United Kingdom)

^b Derbyshire County Primary Care Trust   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; FIBRINOLYTIC AGENT;

BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DRUG USE; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERTENSION; LOW DRUG DOSE; PRACTICE GUIDELINE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SHORT SURVEY; META ANALYSIS; OFF LABEL DRUG USE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

ASPIRIN; CARDIOVASCULAR DISEASES; FIBRINOLYTIC AGENTS; HUMANS; OFF-LABEL USE; PRACTICE GUIDELINES AS TOPIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 77951605056     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c1805     Document Type: Short Survey

References (14)

1. Fourth Joint Taskforce of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). European guidelines on cardiovascular disease prevention in clinical practice: full text. Eur J Cardio Prev Rehab 2007;14:S1-113.
2. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.[Abstract/Free Full Text]
3. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease: a national clinical guideline. 2007. www.sign.ac.uk/pdf/sign97.pdf
4. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 2005;91:v1-52.[Free Full Text]
5. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849- 1860[CrossRef][Web of Science][Medline]
6. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analyis. BMJ 2000;321:1183-1187[Abstract/Free Full Text]
7. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313[Abstract/Free Full Text] (Pubitemid 43112959)
8. Lip GYH, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database of Systematic Reviews 2004;(3):CD003186.
9. De Beradis G, Sacco M, Strippoli GFM, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ 2009;339:b4531.[Abstract/Free Full Text]
10. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303:841- 848[Abstract/Free Full Text]
11. Aspirin for primary prevention of cardiovascular disease? Drug Ther Bull 2009;47:122-125 [Abstract/Free Full Text]
12. National Collaborating Centre for Chronic Conditions. Type 2 diabetes: national clinical guideline for management in primary and secondary care (update). 2008. www.nice.org.uk/nicemedia/pdf/CG66FullGuideline0509.pdf
13. Scottish Intercollegiate Guidelines Network. Management of diabetes: a national clinical guideline. March 2010. http://www.sign.ac.uk/pdf/sign116.pdf
14. Sever PS, BHS working party. Aspirin and primary prevention: BHS reaffirms its guidance. BMJ 2010;340:c1183.[Free Full Text]